ID: ALA3125276

Max Phase: Preclinical

Molecular Formula: C24H27N5O6

Molecular Weight: 481.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCc1cc(C(=O)N[C@@H]2C[C@@H](C(=O)NCC(=O)OC)N(C(=O)c3coc4ccccc34)C2)n(C)n1

Standard InChI:  InChI=1S/C24H27N5O6/c1-4-14-9-18(28(2)27-14)23(32)26-15-10-19(22(31)25-11-21(30)34-3)29(12-15)24(33)17-13-35-20-8-6-5-7-16(17)20/h5-9,13,15,19H,4,10-12H2,1-3H3,(H,25,31)(H,26,32)/t15-,19+/m1/s1

Standard InChI Key:  DOSNVIYGLIAOIS-BEFAXECRSA-N

Associated Targets(non-human)

Mycobacterium tuberculosis 203094 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Enoyl-[acyl-carrier-protein] reductase 1329 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 481.51Molecular Weight (Monoisotopic): 481.1961AlogP: 1.03#Rotatable Bonds: 7
Polar Surface Area: 135.77Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 0HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.79CX Basic pKa: 2.04CX LogP: 0.16CX LogD: 0.16
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.48Np Likeness Score: -1.19

References

1. Encinas L, O'Keefe H, Neu M, Remuiñán MJ, Patel AM, Guardia A, Davie CP, Pérez-Macías N, Yang H, Convery MA, Messer JA, Pérez-Herrán E, Centrella PA, Alvarez-Gómez D, Clark MA, Huss S, O'Donovan GK, Ortega-Muro F, McDowell W, Castañeda P, Arico-Muendel CC, Pajk S, Rullás J, Angulo-Barturen I, Alvarez-Ruíz E, Mendoza-Losana A, Ballell Pages L, Castro-Pichel J, Evindar G..  (2014)  Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,  57  (4): [PMID:24450589] [10.1021/jm401326j]

Source